Boundless Bio, Inc. (BOLD) income statement
BOLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.40−0.01 (-0.41%)
Close on Nov 18, 2026Market cap $54.60MP/E –Yield –
Boundless Bio, Inc. financial ratios
See a number that looks wrong?
Close on Nov 18, 2026Market cap $54.60MP/E –Yield –
See a number that looks wrong?
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Returns on capital | ||||
| Return on equity | -46.7% | -554.9% | 47.4% | – |
| Return on assets | -32.0% | -38.9% | -38.1% | – |
| Return on tangible assets | -32.0% | -38.9% | -38.1% | – |
| Return on capital employed | -37.1% | -46.0% | -45.5% | – |
| NOPAT | -$50.21M | -$57.88M | -$43.29M | – |
| Cash flow quality | ||||
| OCF / Net income | 0.80 | 0.93 | 0.95 | – |
| FCF / OCF | 101.2% | 104.2% | 101.4% | – |
| FCF / Net income | 0.81 | 0.97 | 0.96 | – |
| FCF / EBITDA | 75.8% | 87.8% | 88.2% | – |
| Unlevered free cash flow | -$47.21M | -$63.38M | -$47.49M | – |
| Levered free cash flow | -$47.21M | -$63.38M | -$47.49M | – |
| Efficiency | ||||
| CapEx to OCF | -1.2% | -4.2% | -1.4% | – |
| CapEx to depreciation | 0.44 | 2.34 | 0.66 | – |
| Liquidity | ||||
| Current ratio | 8.74 | 18.98 | 13.27 | – |
| Quick ratio | 8.74 | 18.98 | 13.27 | – |
| Cash ratio | 8.58 | 18.70 | 12.96 | – |
| Working capital | $97.07M | $146.26M | $114.85M | – |
| Net current asset value | $51.21M | $98.62M | $114.85M | – |
| Leverage | ||||
| Assets to equity | 1.59 | 1.37 | -1.02 | – |
| Per share | ||||
| EPS (basic) | -2.60 | -3.85 | -40.65 | – |
| EPS (diluted) | -2.60 | -3.85 | -40.65 | – |
| Book value per share | 4.40 | 6.76 | -101,828.53 | – |
| Tangible book value per share | 4.40 | 6.76 | -101,828.53 | – |
| Cash per share | 4.80 | 6.82 | 97,205.13 | – |
| Operating cash flow per share | -2.08 | -2.73 | -37,544.07 | – |
| Free cash flow per share | -2.11 | -2.84 | -38,051.28 | – |
| CapEx per share | 0.02 | 0.11 | 507.21 | – |
| Valuation at period end | ||||
| Market cap | $26.86M | $64.54M | – | – |
| Enterprise value | -$90.74M | -$102.56M | – | – |
| P/B | 0.3x | 0.4x | – | – |
| P/TBV | 0.3x | 0.4x | – | – |
| P/OCF | -0.6x | -1.1x | – | – |
| EV/EBITDA | 1.5x | 1.4x | – | – |
| EV/EBIT | 1.4x | 1.4x | – | – |
| EV/OCF | 1.9x | 1.7x | – | – |
| EV/FCF | 1.9x | 1.6x | – | – |
| Earnings yield | -216.6% | -101.3% | – | – |
| FCF yield | -175.7% | -98.2% | – | – |
| Per employee | ||||
| Total employees | 28 | 64 | 64 | 64 |
| Operating profit per employee | -$2.27M | -$1.14M | -$856.19K | – |
| Net income per employee | -$2.08M | -$1.02M | -$772.41K | – |
| Free cash flow per employee | -$1.69M | -$990.27K | -$742.00K | – |
| Growth | ||||
| EBIT 1Y growth | 13.3% | -33.7% | – | – |
| EBITDA 1Y growth | 13.7% | -34.1% | – | – |
| Net income 1Y growth | 11.0% | -32.2% | – | – |
| Diluted EPS 1Y growth | 32.5% | 90.5% | – | – |
| Operating cash flow 1Y growth | 23.3% | -29.8% | – | – |
| Free cash flow 1Y growth | 25.5% | -33.5% | – | – |
| CapEx 1Y growth | -78.5% | 300.6% | – | – |
| Total assets 1Y growth | -23.9% | 58.9% | – | – |
| Total equity 1Y growth | -34.5% | 218.5% | – | – |
Every figure here is calculated from standardized financial statements — hover a row name for the formula — not reported by the company. Valuation multiples use the closing price at the end of that period, not today's price.